BMF-219, a covalent binding menin inhibitor, is being tested in adult AML and ALL patients with KMT2Ar or NPM1-m, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic lymphoma (CLL), and multiple myeloma (MM) (COVALENT-101, NCT05153330). This evidence concerns the gene NPM1 and diffuse large B-cell lymphoma.